2024
Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design
Gross R, Thaweethai T, Rosenzweig E, Chan J, Chibnik L, Cicek M, Elliott A, Flaherman V, Foulkes A, Witvliet M, Gallagher R, Gennaro M, Jernigan T, Karlson E, Katz S, Kinser P, Kleinman L, Lamendola-Essel M, Milner J, Mohandas S, Mudumbi P, Newburger J, Rhee K, Salisbury A, Snowden J, Stein C, Stockwell M, Tantisira K, Thomason M, Truong D, Warburton D, Wood J, Ahmed S, Akerlundh A, Alshawabkeh A, Anderson B, Aschner J, Atz A, Aupperle R, Baker F, Balaraman V, Banerjee D, Barch D, Baskin-Sommers A, Bhuiyan, Bind M, Bogie A, Bradford T, Buchbinder N, Bueler E, Bükülmez H, Casey B, Chang L, Chrisant M, Clark D, Clifton R, Clouser K, Cottrell L, Cowan K, D’Sa V, Dapretto M, Dasgupta S, Dehority W, Dionne A, Dummer K, Elias M, Esquenazi-Karonika S, Evans D, Faustino E, Fiks A, Forsha D, Foxe J, Friedman N, Fry G, Gaur S, Gee D, Gray K, Handler S, Harahsheh A, Hasbani K, Heath A, Hebson C, Heitzeg M, Hester C, Hill S, Hobart-Porter L, Hong T, Horowitz C, Hsia D, Huentelman M, Hummel K, Irby K, Jacobus J, Jacoby V, Jone P, Kaelber D, Kasmarcak T, Kluko M, Kosut J, Laird A, Landeo-Gutierrez J, Lang S, Larson C, Lim P, Lisdahl K, McCrindle B, McCulloh R, McHugh K, Mendelsohn A, Metz T, Miller J, Mitchell E, Morgan L, Müller-Oehring E, Nahin E, Neale M, Ness-Cochinwala M, Nolan S, Oliveira C, Osakwe O, Oster M, Payne R, Portman M, Raissy H, Randall I, Rao S, Reeder H, Rosas J, Russell M, Sabati A, Sanil Y, Sato A, Schechter M, Selvarangan R, Tejtel S, Shakti D, Sharma K, Squeglia L, Srivastava S, Stevenson M, Szmuszkovicz J, Talavera-Barber M, Teufel R, Thacker D, Trachtenberg F, Udosen M, Warner M, Watson S, Werzberger A, Weyer J, Wood M, Yin H, Zempsky W, Zimmerman E, Dreyer B, Consortium O. Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design. PLOS ONE 2024, 19: e0285635. PMID: 38713673, PMCID: PMC11075869, DOI: 10.1371/journal.pone.0285635.Peer-Reviewed Original ResearchConceptsYoung adultsClinical courseAdolescent Brain Cognitive DevelopmentCaregiver-child pairsLong-term outcomesObservational cohort studyOutcomes of COVID-19De novo cohortAdolescent Brain Cognitive Development StudySociodemographic correlatesCommunity partnersBaseline assessmentLongitudinal follow-upPotential therapeutic interventionsPediatric protocolsCohort studyCollaborative partnershipsProspective cohortFollow-upStudy protocolFederal partnersNIH Researching COVIDLong-term outcomes of COVID-19Enhanced recoveryData collectionGuidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce
Willis Z, Oliveira C, Abzug M, Anosike B, Ardura M, Bio L, Boguniewicz J, Chiotos K, Downes K, Grapentine S, Hersh A, Heston S, Hijano D, Huskins W, James S, Jones S, Lockowitz C, Lloyd E, MacBrayne C, Maron G, McDonough M, Miller C, Morton T, Olivero R, Orscheln R, Schwenk H, Singh P, Soma V, Sue P, Vora S, Nakamura M, Wolf J. Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce. Journal Of The Pediatric Infectious Diseases Society 2024, 13: 159-185. PMID: 38339996, DOI: 10.1093/jpids/piad116.Peer-Reviewed Original ResearchConceptsRisk factorsRisk stratificationPediatric intensive care medicineEffects of therapyNon-hospitalized childrenPediatric infectious diseasesSevere COVID-19Cases of infectionMeta-analysis of dataIntensive care medicineClinical characteristicsPreventive therapyPediatric populationManagement of COVID-19Fatal infectionConsensus statementSevere illnessTherapyMeta-analysisTherapeutic interventionsSARS-CoV-2Expert consensusCare medicineRe-convenedGuidance statements
2023
Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine–associated myocarditis
Barmada A, Klein J, Ramaswamy A, Brodsky N, Jaycox J, Sheikha H, Jones K, Habet V, Campbell M, Sumida T, Kontorovich A, Bogunovic D, Oliveira C, Steele J, Hall E, Pena-Hernandez M, Monteiro V, Lucas C, Ring A, Omer S, Iwasaki A, Yildirim I, Lucas C. Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine–associated myocarditis. Science Immunology 2023, 8: eadh3455-eadh3455. PMID: 37146127, PMCID: PMC10468758, DOI: 10.1126/sciimmunol.adh3455.Peer-Reviewed Original ResearchConceptsMRNA vaccinesSARS-CoV-2 mRNA vaccinesSARS-CoV-2 mRNA vaccinationC-reactive protein levelsB-type natriuretic peptidePeripheral blood mononuclear cellsCardiac tissue inflammationDeep immune profilingSerum soluble CD163Vaccine-associated myocarditisCohort of patientsBlood mononuclear cellsCytotoxic T cellsLate gadolinium enhancementHypersensitivity myocarditisElevated troponinMRNA vaccinationImaging abnormalitiesNK cellsImmune profilingKiller cellsMyeloid responseNatriuretic peptideHumoral mechanismsInflammatory cytokinesRoutine saliva testing for SARS-CoV-2 in children: Methods for partnering with community childcare centers
Rayack E, Askari H, Zirinsky E, Lapidus S, Sheikha H, Peno C, Kazemi Y, Yolda-Carr D, Liu C, Grubaugh N, Ko A, Wyllie A, Spatz E, Oliveira C, Bei A. Routine saliva testing for SARS-CoV-2 in children: Methods for partnering with community childcare centers. Frontiers In Public Health 2023, 11: 1003158. PMID: 36817891, PMCID: PMC9936085, DOI: 10.3389/fpubh.2023.1003158.Peer-Reviewed Original ResearchConceptsParents/guardiansOnline patient portalYounger age groupsSARS-CoV-2Age groupsSurveillance programSaliva collectionSARS-CoV-2 testingSARS-CoV-2 screeningWeekly saliva samplesRT-PCR testingChildcare centre staffCritical age groupRoutine surveillance toolRoutine testing programsChildcare centersCOVID-19 transmissionAsymptomatic screeningSaliva collection methodNasal swabsPatient portalsSymptomatic testingPublic health dataSaliva samplesChildcare facilitiesClinical Epidemiology of Pediatric Coronavirus Disease 2019 and its Postacute Sequelae
Habet V, Oliveira C. Clinical Epidemiology of Pediatric Coronavirus Disease 2019 and its Postacute Sequelae. Seminars In Respiratory And Critical Care Medicine 2023, 44: 066-074. PMID: 36646086, PMCID: PMC9926930, DOI: 10.1055/s-0042-1759566.Commentaries, Editorials and LettersMeSH KeywordsChildCOVID-19Disease ProgressionHumansPost-Acute COVID-19 SyndromeQuality of LifeSARS-CoV-2ConceptsClinical epidemiologyCOVID-19Pediatric coronavirus disease 2019Pediatric COVID-19Multisystem inflammatory syndromeAcute respiratory illnessCoronavirus disease 2019 (COVID-19) pandemicCoronavirus disease 2019Disease 2019 pandemicQuality of lifeHealth care systemBenign illnessCardiogenic shockInflammatory syndromeLong COVIDPostinfectious sequelaePediatric deathsRespiratory illnessPostacute sequelaeDisease 2019Mortality rateConsiderable burdenAge groupsCare systemSequelae
2022
Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents
Oliveira CR, Niccolai LM, Sheikha H, Elmansy L, Kalinich CC, Grubaugh ND, Shapiro ED, Billig K, Breban M, Brito A, Earnest R, Fauver J, Koch T, Ott I, Petrone M, Vogels C, Pham K, Tikhonova I, Castaldi C, Mane S, Bilguvar K, De Kumar B, Ferguson D, Kerantzas N, Landry M, Peaper D, Schulz W. Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents. JAMA Network Open 2022, 5: e220935. PMID: 35238933, PMCID: PMC8895259, DOI: 10.1001/jamanetworkopen.2022.0935.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionCase-control studyVaccine effectivenessBNT162b2 vaccineSARS-CoV-2Medical recordsAsymptomatic SARS-CoV-2 infectionBNT162b2 COVID-19 vaccineRetrospective case-control studyRT-PCR test resultsSARS-CoV-2 testUS adolescentsReverse transcription polymerase chain reaction testConditional logistic regression modelsTranscription polymerase chain reaction testDoses of vaccineControl participantsClinical trial populationsRelevant clinical dataCase participantsCOVID-19 vaccinePositive test resultsChain reaction testCounty of residenceNegative test resultsUpdated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents
Wolf J, Abzug MJ, Anosike BI, Vora SB, Waghmare A, Sue PK, Olivero RM, Oliveira CR, James SH, Morton TH, Maron GM, Young JL, Orscheln RC, Schwenk HT, Bio LL, Willis ZI, Lloyd EC, Hersh AL, Huskins CW, Soma VL, Ratner AJ, Hayes M, Downes K, Chiotos K, Grapentine SP, Wattier RL, Lamb GS, Zachariah P, Nakamura MM. Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents. Journal Of The Pediatric Infectious Diseases Society 2022, 11: 177-185. PMID: 35107571, PMCID: PMC8903349, DOI: 10.1093/jpids/piab124.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMonoclonal antibody therapyPediatric infectious diseasesAntibody therapyEmergency use authorizationSevere diseasePostexposure prophylaxisHigh riskCOVID-19Severe acute respiratory syndrome coronavirus 2Certain high-risk conditionsSpecific monoclonal antibody therapyAcute respiratory syndrome coronavirus 2Infectious diseasesRespiratory syndrome coronavirus 2Moderate COVID-19Pediatric critical care medicineSyndrome coronavirus 2Coronavirus disease 2019Critical care medicineHigh-risk conditionsSeries of teleconferencesHigh-risk exposureBamlanivimab monotherapyInfusion reactionsControlled Trials
2021
The clinical epidemiology of coronavirus disease 2019 in children and adolescents mirrors the widening gap in healthcare disparities
Zirinsky E, Paintsil E, Oliveira CR. The clinical epidemiology of coronavirus disease 2019 in children and adolescents mirrors the widening gap in healthcare disparities. Current Opinion In Pediatrics 2021, 33: 281-285. PMID: 33871422, PMCID: PMC8635086, DOI: 10.1097/mop.0000000000001018.Commentaries, Editorials and LettersMeSH KeywordsAdolescentChildCOVID-19Healthcare DisparitiesHispanic or LatinoHumansPandemicsSARS-CoV-2ConceptsClinical epidemiologyRespiratory diseaseSARS-CoV-2-related deathAcute respiratory syndrome coronavirus 2 pandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemicSevere lower respiratory diseaseHealth disparitiesSARS-CoV-2 infectionLongstanding health disparitiesKawasaki-like syndromeLower respiratory diseaseCoronavirus 2 pandemicCoronavirus disease 2019Upper respiratory diseaseSARS-CoV-2Ethnic health disparitiesPandemics/epidemicsCardiovascular shockInfluenza seasonDisease 2019Healthcare disparitiesUS populationEthnic disparitiesHispanic childrenMore childrenInitial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents
Wolf J, Abzug MJ, Wattier RL, Sue PK, Vora SB, Zachariah P, Dulek DE, Waghmare A, Olivero R, Downes KJ, James SH, Pinninti SG, Yarbrough A, Aldrich ML, MacBrayne CE, Soma VL, Grapentine SP, Oliveira CR, Hayes M, Kimberlin DW, Jones SB, Bio LL, Morton TH, Hankins JS, Marόn-Alfaro G, Timberlake K, Young JL, Orscheln RC, Schwenk HT, Goldman DL, Groves HE, Huskins WC, Rajapakse NS, Lamb GS, Tribble AC, Lloyd E, Hersh AL, Thorell EA, Ratner AJ, Chiotos K, Nakamura MM. Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents. Journal Of The Pediatric Infectious Diseases Society 2021, 10: 629-634. PMID: 33388760, PMCID: PMC7799019, DOI: 10.1093/jpids/piaa175.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMonoclonal antibody therapyHigh-risk groupAntibody therapyEmergency use authorizationCOVID-19Moderate coronavirus disease 2019Pediatric intensive care medicinePediatric-specific evidenceTreatment of mildPediatric infectious diseasesHigh-quality evidenceCoronavirus disease 2019Intensive care medicineSeries of teleconferencesREGN-COV2Infusion reactionsPediatric HematologyTimely administrationRisk factorsRoutine administrationDisease 2019Severe diseaseCare medicineHigh riskModest benefit
2020
Severe Acute Respiratory Syndrome Coronavirus 2 Testing in Children in a Large Regional US Health System During the Coronavirus Disease 2019 Pandemic.
Peaper DR, Murdzek C, Oliveira CR, Murray TS. Severe Acute Respiratory Syndrome Coronavirus 2 Testing in Children in a Large Regional US Health System During the Coronavirus Disease 2019 Pandemic. The Pediatric Infectious Disease Journal 2020, 40: 175-181. PMID: 33399431, PMCID: PMC8852689, DOI: 10.1097/inf.0000000000003024.Peer-Reviewed Original ResearchConceptsYale New Haven Health SystemSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Syndrome coronavirus 2Subset of childrenPediatric casesHealth systemCycle threshold valuesCoronavirus 2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNACross-sectional time-series studyCoronavirus disease 2019 (COVID-19) testingPositive pediatric casesSimilar cycle threshold valuesCoronavirus disease 2019 (COVID-19) pandemicUpper respiratory tractCoronavirus disease 2019Large health systemYears of ageDisease 2019 pandemicUS health systemAmbulatory locationsVirology resultsAsymptomatic children